JP2024514281A5 - - Google Patents
Info
- Publication number
- JP2024514281A5 JP2024514281A5 JP2023552335A JP2023552335A JP2024514281A5 JP 2024514281 A5 JP2024514281 A5 JP 2024514281A5 JP 2023552335 A JP2023552335 A JP 2023552335A JP 2023552335 A JP2023552335 A JP 2023552335A JP 2024514281 A5 JP2024514281 A5 JP 2024514281A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- inhibitor
- pharmaceutical product
- src
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21170037 | 2021-04-23 | ||
| EP21170037.2 | 2021-04-23 | ||
| PCT/EP2022/060469 WO2022223651A1 (en) | 2021-04-23 | 2022-04-21 | Prevention or mitigation of nk cell engaging agent-related adverse effects |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024514281A JP2024514281A (ja) | 2024-04-01 |
| JP2024514281A5 true JP2024514281A5 (https=) | 2025-04-11 |
Family
ID=75659842
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023552335A Pending JP2024514281A (ja) | 2021-04-23 | 2022-04-21 | Ｎｋ細胞係合剤関連の有害作用の防止または軽減 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240058443A1 (https=) |
| EP (1) | EP4326271A1 (https=) |
| JP (1) | JP2024514281A (https=) |
| CN (1) | CN117222412A (https=) |
| TW (1) | TW202304526A (https=) |
| WO (1) | WO2022223651A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111201030B (zh) | 2017-07-25 | 2024-11-01 | 真和制药有限公司 | 通过阻断tim-3和其配体的相互作用治疗癌症 |
| WO2020160156A2 (en) | 2019-01-30 | 2020-08-06 | Immutics, Inc. | Anti-gal3 antibodies and uses thereof |
| EP4157338A4 (en) | 2020-05-26 | 2024-11-13 | TrueBinding, Inc. | METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING |
| CN121194797A (zh) * | 2023-05-08 | 2025-12-23 | 复旦大学 | 抗炎药物在抵抗cart治疗所引起的crs中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0368684B2 (en) | 1988-11-11 | 2004-09-29 | Medical Research Council | Cloning immunoglobulin variable domain sequences. |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| FI941572A7 (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| CA2704600C (en) | 1999-04-09 | 2016-10-25 | Kyowa Kirin Co., Ltd. | A method for producing antibodies with increased adcc activity |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| NZ571596A (en) | 2001-08-03 | 2010-11-26 | Glycart Biotechnology Ag | Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| CA2463879C (en) | 2001-10-25 | 2012-12-04 | Genentech, Inc. | Glycoprotein compositions |
| US20040093621A1 (en) | 2001-12-25 | 2004-05-13 | Kyowa Hakko Kogyo Co., Ltd | Antibody composition which specifically binds to CD20 |
| CA2471551C (en) | 2001-12-27 | 2014-09-30 | Glycofi, Inc. | Methods to engineer mammalian-type carbohydrate structures |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| EP1498490A4 (en) | 2002-04-09 | 2006-11-29 | Kyowa Hakko Kogyo Kk | PROCESS FOR PREPARING ANTIBODY COMPOSITION |
| CA2481658A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Method of enhancing of binding activity of antibody composition to fcy receptor iiia |
| ATE503829T1 (de) | 2002-04-09 | 2011-04-15 | Kyowa Hakko Kirin Co Ltd | Zelle mit erniedrigter oder deletierter aktivität eines am gdp-fucosetransport beteiligten proteins |
| CA2481925A1 (en) | 2002-04-09 | 2003-10-16 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for patients having human fc.gamma.riiia |
| BR0309145A (pt) | 2002-04-09 | 2005-02-01 | Kyowa Hakko Kogyo Kk | Células das quais o genoma é modificado |
| EP1539966B1 (en) | 2002-09-12 | 2010-06-30 | Greenovation Biotech GmbH | Protein production method |
| TWI335821B (en) | 2002-12-16 | 2011-01-11 | Genentech Inc | Immunoglobulin variants and uses thereof |
| WO2004057002A2 (en) | 2002-12-20 | 2004-07-08 | Greenovation Biotech Gmbh | Production of heterologous glycosylated proteins in bryophyte cells |
| CA2512729C (en) | 2003-01-09 | 2014-09-16 | Macrogenics, Inc. | Identification and engineering of antibodies with variant fc regions and methods of using same |
| EP2248892B1 (en) | 2003-01-22 | 2015-04-22 | Roche Glycart AG | Fusion constructs and use of same to produce antibodies with increased FC receptor binding affinity and effector function |
| KR20230148844A (ko) * | 2016-03-29 | 2023-10-25 | 유니버시티 오브 써던 캘리포니아 | 암을 표적하는 키메라 항원 수용체 |
| WO2018220099A1 (en) * | 2017-06-02 | 2018-12-06 | F. Hoffmann-La Roche Ag | Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer |
| SG11201900344YA (en) * | 2016-07-15 | 2019-02-27 | Novartis Ag | Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor |
| WO2020169698A1 (en) * | 2019-02-21 | 2020-08-27 | F. Hoffmann-La Roche Ag | Sensitization of cancer cells to tnf by bet inhibition |
-
2022
- 2022-04-21 WO PCT/EP2022/060469 patent/WO2022223651A1/en not_active Ceased
- 2022-04-21 JP JP2023552335A patent/JP2024514281A/ja active Pending
- 2022-04-21 CN CN202280029611.1A patent/CN117222412A/zh active Pending
- 2022-04-21 EP EP22722286.6A patent/EP4326271A1/en active Pending
- 2022-04-22 TW TW111115381A patent/TW202304526A/zh unknown
-
2023
- 2023-10-20 US US18/491,669 patent/US20240058443A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024514281A5 (https=) | ||
| CN1191850C (zh) | 使用抗cd20嵌合抗体治疗循环肿瘤细胞相关的血液恶性肿瘤 | |
| Antin et al. | Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease | |
| Remberger et al. | Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation | |
| Prieto-Peña et al. | Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update | |
| WO2002096461A1 (en) | Use of anti-tnf antibodies as drugs in treating septic disorders of anemic patients | |
| JP2018138551A (ja) | 関節リウマチの治療 | |
| JP2023547523A5 (https=) | ||
| JP2023542212A5 (https=) | ||
| Danese et al. | Biological Therapies for Inflammatory Bowel Disease: Research DrivesClinics | |
| Dariushnejad et al. | Rheumatoid arthritis: current therapeutics compendium | |
| US10611821B2 (en) | Methods for treating or reducing liver diseases by administering oral composition comprising TNF receptor fusion proteins | |
| KR20230005142A (ko) | 인터루킨 억제제와 조합된 clever-1 억제제를 통한 질환의 치료 | |
| Popa et al. | Cytokine production from stimulated whole blood cultures in rheumatoid arthritis patients treated with various TNF blocking agents. | |
| AU756167B2 (en) | Application of TNF antagonists as medicaments for treating septic diseases | |
| Darville et al. | Intravenous immunoglobulin modulates human mononuclear phagocyte tumor necrosis factor-α production in vitro | |
| WO2020234833A1 (en) | Method for treating, preventing, inhibiting or reducing cytokine release | |
| CZ20032672A3 (cs) | CD25 vazebná molekula pro použití při prevenci nebo léčení některých nemocí u pacientů rezistentních na léčbu steroidy | |
| CN112292130A (zh) | β-葡聚糖和CD40激动剂组合免疫疗法 | |
| van Deventer et al. | Monoclonal antibody therapy of inflammatory bowel disease. | |
| RU2318537C2 (ru) | Применение cd25-связывающих молекул для лечения пациентов, устойчивых к стероидам | |
| RU2024113955A (ru) | Антитела, активирующие бутирофилин (btn) 3а, для применения в способах лечения инфекционных заболеваний | |
| WO2026094824A1 (ja) | Ｐａｄ阻害剤の自己免疫性関節炎の治療または予防のための使用 | |
| Elmslie | Drug Therapy for Rheumatoid Arthritis | |
| RU2008127884A (ru) | Способы применения cd40-связывающих веществ |